Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: The TROPIC study in France;Cabazitaxel dans le cancer de la prostate métastatique résistant à la castration ayant progressé pendant ou après traitement par docétaxel: L'expérience française de l'essai TROPIC

Bulletin du Cancer

Volumn 99, Issue 7-8, 2012, Pages 731-741

  Pouessel, Damien ^a   Oudard, Stéphane ^b   Gravis, Gwenaëlle ^c   Priou, Frank ^d   Shen, Liji ^e   Culine, Stéphane ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d Centre Hospitalier Departemental   (France)

^e Global Health Outcomes and Market Access   (United States)

Author keywords

Cabazitaxel; Cancer; Chemotherapy; France; Prostate

Indexed keywords

CABAZITAXEL; DOCETAXEL; MITOXANTRONE; PREDNISONE;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL;

EID: 84863978920     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1608     Document Type: Article

References (16)

1. Villers A, Grosclaude P. Épidémiologie du cancer de la prostate: article de revue. Med Nucl 2008;32:2-4.
2. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827-41. (Pubitemid 15062911)
3. Berry DL, Moinpour CM, Jiang CS, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustineto mitoxantrone and prednisone. J Clin Oncol 2006;24:2828-35. (Pubitemid 46630582)
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20. (Pubitemid 39315318)
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
6. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64. (Pubitemid 26185452)
7. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
8. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22.
9. Parker C, Heinrich D, O'Sullivan JM, et al. 36th European Society for Medical Oncology (ESMO) congress. Stockholm, Sweden, 2011 (abstract 1LBA).
10. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
11. Scher HI, Fizazi K, Saad F, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012;30 (suppl. 5) (abstract LBA1).
12. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet 2010;376:1147-54.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
14. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
15. Melzack R. The McGill pain questionnaire: major properties and scoring methods. Pain 1975;1:277-99.
16. Cancer therapy evaluation program. Common terminology criteria for adverse events, version 3.0, published August 9, 2006 (dernière consultation:septembre 14, 2010;disponible sur: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm#ctc-30).